Stammdaten
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Unternehmen & Branche
| Name | OnKure Therapeutics, Inc. |
|---|---|
| Ticker | OKUR |
| CIK | 0001637715 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 70,6 Mio. USD |
| Beta | 0,15 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -59,517,000 | -4.40 | 62,117,000 | 56,184,000 | |
| 2025-09-30 | 10-Q | -14,699,000 | -1.09 | 72,835,000 | 66,428,000 | |
| 2025-06-30 | 10-Q | -15,390,000 | -1.14 | 86,070,000 | 78,166,000 | |
| 2025-03-31 | 10-Q | -15,925,000 | -1.19 | 99,882,000 | 90,648,000 | |
| 2024-12-31 | 10-K | 0 | -52,673,000 | -15.28 | 114,907,000 | 103,828,000 |
| 2024-12-31 | 10-Q | -17,442,000 | 114,907,000 | 103,828,000 | ||
| 2024-09-30 | 10-Q | -11,556,000 | -36.55 | 77,645,000 | -135,050,000 | |
| 2024-06-30 | 10-Q | -14,139,000 | -44.82 | 78,717,000 | -123,577,000 | |
| 2024-03-31 | 10-Q | -9,536,000 | -30.37 | 84,639,000 | -111,261,000 | |
| 2023-12-31 | 10-K | -35,311,000 | -124.41 | 35,734,000 | -101,842,000 | |
| 2023-09-30 | 10-Q | -19,196,000 | -5.68 | 130,388,000 | 114,944,000 | |
| 2023-06-30 | 10-Q | -19,531,000 | -0.65 | 148,039,000 | 132,528,000 | |
| 2023-03-31 | 10-Q | -15,107,000 | -0.60 | 98,868,000 | 87,084,000 | |
| 2022-12-31 | 10-K | -51,955,000 | -2.12 | 108,182,000 | -54,418,000 | |
| 2022-09-30 | 10-Q | -13,007,000 | -0.53 | 122,504,000 | 112,045,000 | |
| 2022-06-30 | 10-Q | -12,312,000 | -0.50 | 133,608,000 | 124,157,000 | |
| 2022-03-31 | 10-Q | -13,036,000 | -0.53 | 144,412,000 | 135,318,000 | |
| 2021-12-31 | 10-K | -39,770,000 | -2.19 | 154,024,000 | 147,211,000 | |
| 2021-09-30 | 10-Q | -12,735,000 | -0.52 | 162,943,000 | 156,208,000 | |
| 2021-06-30 | 10-Q | -9,216,000 | -0.43 | 171,304,000 | 167,551,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-22 | Leverone Jason A. | Officer, Chief Financial Officer | Open Market Sale | -302 | 2.97 | -896.25 | -0,1% | |
| 2025-12-22 | Saccomano Nicholas A | Director, Officer, President and CEO | Open Market Sale | -87 | 2.97 | -258.19 | 0,0% | |
| 2025-09-22 | Saccomano Nicholas A | Director, Officer, President and CEO | Open Market Sale | -88 | 2.62 | -230.87 | 0,0% | |
| 2025-09-22 | Leverone Jason A. | Officer, Chief Financial Officer | Open Market Sale | -303 | 2.62 | -794.92 | -0,1% | |
| 2025-06-23 | Leverone Jason A. | Officer, Chief Financial Officer | Open Market Sale | -303 | 2.38 | -722.41 | -0,1% | |
| 2025-06-23 | Saccomano Nicholas A | Director, Officer, President and CEO | Open Market Sale | -88 | 2.38 | -209.81 | 0,0% | |
| 2025-05-15 | ACORN BIOVENTURES, L.P. | 10% Owner | Open Market Purchase | 1,129,730 | 1.85 | 2,090,000.50 | +348,1% | |
| 2025-05-15 | ACORN BIOVENTURES, L.P. | 10% Owner | Open Market Purchase | 270,270 | 1.85 | 499,999.50 | +83,3% | |
| 2025-05-15 | Cormorant Asset Management, LP | Open Market Sale | -1,813,439 | 1.85 | -3,363,022.63 | -560,1% | ||
| 2025-05-12 | Cormorant Asset Management, LP | 10% Owner | Open Market Sale | -24,300 | 1.99 | -48,235.50 | -8,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.